Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 7682 results

  1. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Aflibercept for untreated diabetic macular oedema TS ID 10621

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Lymphatico-venous anastomosis for chronic lymphoedema

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  5. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  9. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable ID 6272

      Status ...

    Health technology evaluations
    Topic selection

  10. Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse TS ID 11900

      Status ...

    Health technology evaluations
    Topic selection

  11. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development [GID-TA10486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969

      Status ...

    Technology appraisal guidance
    Topic selection

  13. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    Awaiting development [GID-TA11341] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development